
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Reports Completion Of TIVO-3 Trial Futility Analysis
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported the conclusion of a pre-planned futility assessment of the Phase III TIVO-3 study, the firm’s randomized, controlled, open-label trial to












